The observed positive effects of ALM16 against hepatic steatosis and liver damage were, at least partly, shown to be mediated by the downregulation of SREBP-1c and FAS expression and upregulation of CPT-1 expression, through the modulation of AMPK and ACC signaling, in the established NAFLD in vivo model. The gene discussed is FAS; the disease is fatty liver disease.